Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Gout
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
192
States / cities
Binghamton, Alabama • Birmingham, Alabama • Huntsville, Alabama + 189 more
Conditions
Gastroesophageal Reflux Disease
Interventions
Lansoprazole microgranules suspension, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Month to 11 Months
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux

NCT01317472
Conditions
Laryngopharyngeal Reflux
Interventions
dexlansoprazole, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Dysphonia
Interventions
Lansoprazole, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
3 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 92 more
Conditions
Erosive Esophagitis
Interventions
H008, H008 placebo, Lansoprazole
Drug
Lead sponsor
Jiangsu Carephar Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Terminated Phase 2Phase 3 Interventional Results available

Elucidation of Acid-Induced Pulmonary Inflammation

NCT00361972
Conditions
Gastroesophageal Reflux, Asthma
Interventions
lansoprazole, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Heartburn
Interventions
Lansoprazole
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
30
States / cities
Mobile, Alabama • Little Rock, Alaska • Chandler, Arizona + 26 more
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole MR QD
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
52
States / cities
Hueytown, Alabama • Chandler, Arizona • Sierra Vista, Arizona + 49 more
Conditions
Type 1 Diabetes
Interventions
Sitagliptin and Lansoprazole, Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
11 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
3
States / cities
San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Tucson, Arizona • Anaheim, California • Garden Grove, California + 40 more
Conditions
Asthma, Gastroesophageal Reflux
Interventions
commercially available lansoprazole, matched placebo
Drug
Lead sponsor
Jason Lang, M.D., M.P.H.
Other
Eligibility
6 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Conditions
Diabetes Mellitus Type 1, Autoimmune Diabetes
Interventions
Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd)
Drug · Biological
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
153
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 150 more
Conditions
Heartburn
Interventions
Lanzoprazole
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Hoover, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 23 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2940680 in Healthy Participants

NCT01681186
Conditions
Healthy Participants
Interventions
LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole, Placebo Capsule(s)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis
Interventions
Dexlansoprazole, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
32
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Conditions
Gastroesophageal Reflux Disease
Interventions
IW-3718, Matching Placebo, PPI
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more